Cargando…
A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management
The 2019 novel coronavirus (2019-nCoV), commonly known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19), was first revealed in late 2019 in Wuhan city, Hubei province, China. It was subsequently spread globally and thereby declared as a pandemic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957225/ https://www.ncbi.nlm.nih.gov/pubmed/33732150 http://dx.doi.org/10.3389/fphar.2021.576448 |
_version_ | 1783664608319373312 |
---|---|
author | Shoaib, Muhammad Harris Ahmed, Farrukh Rafiq Sikandar, Muhammad Yousuf, Rabia Ismail Saleem, Muhammad Talha |
author_facet | Shoaib, Muhammad Harris Ahmed, Farrukh Rafiq Sikandar, Muhammad Yousuf, Rabia Ismail Saleem, Muhammad Talha |
author_sort | Shoaib, Muhammad Harris |
collection | PubMed |
description | The 2019 novel coronavirus (2019-nCoV), commonly known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19), was first revealed in late 2019 in Wuhan city, Hubei province, China. It was subsequently spread globally and thereby declared as a pandemic by WHO in March 2020. The disease causes severe acute respiratory illness and is highly contagious due to the fast-onward transmission. As of the mid of November 2020, the disease has affected 220 countries with more than 16 million active cases and 1.3 million deaths worldwide. Males, pregnant women, the elderly, immunosuppressed patients, and those with underlying medical conditions are more vulnerable to the disease than the general healthy population. Unfortunately, no definite treatment is available. Although remdesivir as an antiviral had been approved for use in those above 12 years of age and 40 kg weight group, it has been observed to be ineffective in large-scale SOLIDARITY trials by WHO. Moreover, dexamethasone has been found to increase the recovery rate of ventilated patients; oxygen and inhaled nitric oxide as a vasodilator have been given emergency expanded access. In addition, more than 57 clinical trials are being conducted for the development of the vaccines on various platforms. Two vaccines were found to be significantly promising in phase III results. It is concluded that till the approval of a specific treatment or development of a vaccine against this deadly disease, the preventive measures should be followed strictly to reduce the spread of the disease. |
format | Online Article Text |
id | pubmed-7957225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79572252021-03-16 A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management Shoaib, Muhammad Harris Ahmed, Farrukh Rafiq Sikandar, Muhammad Yousuf, Rabia Ismail Saleem, Muhammad Talha Front Pharmacol Pharmacology The 2019 novel coronavirus (2019-nCoV), commonly known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19), was first revealed in late 2019 in Wuhan city, Hubei province, China. It was subsequently spread globally and thereby declared as a pandemic by WHO in March 2020. The disease causes severe acute respiratory illness and is highly contagious due to the fast-onward transmission. As of the mid of November 2020, the disease has affected 220 countries with more than 16 million active cases and 1.3 million deaths worldwide. Males, pregnant women, the elderly, immunosuppressed patients, and those with underlying medical conditions are more vulnerable to the disease than the general healthy population. Unfortunately, no definite treatment is available. Although remdesivir as an antiviral had been approved for use in those above 12 years of age and 40 kg weight group, it has been observed to be ineffective in large-scale SOLIDARITY trials by WHO. Moreover, dexamethasone has been found to increase the recovery rate of ventilated patients; oxygen and inhaled nitric oxide as a vasodilator have been given emergency expanded access. In addition, more than 57 clinical trials are being conducted for the development of the vaccines on various platforms. Two vaccines were found to be significantly promising in phase III results. It is concluded that till the approval of a specific treatment or development of a vaccine against this deadly disease, the preventive measures should be followed strictly to reduce the spread of the disease. Frontiers Media S.A. 2021-02-26 /pmc/articles/PMC7957225/ /pubmed/33732150 http://dx.doi.org/10.3389/fphar.2021.576448 Text en Copyright © 2021 Shoaib, Ahmed, Sikandar, Yousuf and Saleem. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Shoaib, Muhammad Harris Ahmed, Farrukh Rafiq Sikandar, Muhammad Yousuf, Rabia Ismail Saleem, Muhammad Talha A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management |
title | A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management |
title_full | A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management |
title_fullStr | A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management |
title_full_unstemmed | A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management |
title_short | A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management |
title_sort | journey from sars-cov-2 to covid-19 and beyond: a comprehensive insight of epidemiology, diagnosis, pathogenesis, and overview of the progress into its therapeutic management |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957225/ https://www.ncbi.nlm.nih.gov/pubmed/33732150 http://dx.doi.org/10.3389/fphar.2021.576448 |
work_keys_str_mv | AT shoaibmuhammadharris ajourneyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT ahmedfarrukhrafiq ajourneyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT sikandarmuhammad ajourneyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT yousufrabiaismail ajourneyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT saleemmuhammadtalha ajourneyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT shoaibmuhammadharris journeyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT ahmedfarrukhrafiq journeyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT sikandarmuhammad journeyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT yousufrabiaismail journeyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement AT saleemmuhammadtalha journeyfromsarscov2tocovid19andbeyondacomprehensiveinsightofepidemiologydiagnosispathogenesisandoverviewoftheprogressintoitstherapeuticmanagement |